Mechanisms of Resistance to Anti-CD38 Daratumumab in Multiple Myeloma

被引：86

作者：

Saltarella, Ilaria ^{[1
]}

Desantis, Vanessa ^{[1
]}

Melaccio, Assunta ^{[1
]}

Solimando, Antonio Giovanni ^{[1
]}

Lamanuzzi, Aurelia ^{[1
]}

Ria, Roberto ^{[1
]}

Storlazzi, Clelia Tiziana ^{[2
]}

Mariggio, Maria Addolorata ^{[3
]}

Vacca, Angelo ^{[1
]}

Frassanito, Maria Antonia ^{[3
]}

机构：

[1] Univ Bari Aldo Moro, Unit Internal Med & Clin Oncol, Dept Biomed Sci & Human Oncol, I-70124 Bari, Italy

[2] Univ Bari Aldo Moro, Dept Biol, I-70125 Bari, Italy

[3] Univ Bari Aldo Moro, Dept Biomed Sci & Human Oncol, Unit Gen Pathol, I-70124 Bari, Italy

来源：

CELLS | 2020年 / 9卷 / 01期

关键词：

multiple myeloma; CD38; antigen; daratumumab; drug resistance; MONOCLONAL-ANTIBODY THERAPY; DRUG-RESISTANCE; CD38; EXPRESSION; COMPLEMENT REGULATORS; MEDIATED PHAGOCYTOSIS; ANTITUMOR-ACTIVITY; CELLS; BONE; GAMMA; BORTEZOMIB;

D O I：

10.3390/cells9010167

中图分类号：

Q2 [细胞生物学];

学科分类号：

071009 ; 090102 ;

摘要：

Daratumumab (Dara) is the first-in-class human-specific anti-CD38 mAb approved for the treatment of multiple myeloma (MM). Although recent data have demonstrated very promising results in clinical practice and trials, some patients do not achieve a partial response, and ultimately all patients undergo progression. Dara exerts anti-MM activity via antibody-dependent cell-mediated cytotoxicity (ADCC), antibody-dependent cellular phagocytosis (ADCP), complement-dependent cytotoxicity (CDC), and immunomodulatory effects. Deregulation of these pleiotropic mechanisms may cause development of Dara resistance. Knowledge of this resistance may improve the therapeutic management of MM patients.

引用

页数：14

共 50 条

[21] Variable Serologic Reactivity Associated with Daratumumab (Anti-CD38) Interference
Mo, Y. D.
Banks, K.
Brady, T.
DiGuardo, M.
Gorham, J.
Luckey, C. J.
Wehrli, G.
TRANSFUSION, 2016, 56 : 125A - 126A
[22] Dealing with anti-CD38 (daratumumab) interference in blood compatibility testing
De Vooght, Karen M. K.
Oostendorp, Marlies
van Solinge, Wouter W.
TRANSFUSION, 2016, 56 (03) : 778 - 779
[23] Considerations for pre-transfusion immunohaematology testing in patients receiving the anti-CD38 monoclonal antibody daratumumab for the treatment of multiple myeloma
Quach, Hang
Benson, Simon
Haysom, Helen
Wilkes, Anne-Marie
Zacher, Nicole
Cole-Sinclair, Merrole
Prince, Henry Miles
Mollee, Peter
Spencer, Andrew
Ho, Phoebe Joy
Harrison, Simon J.
Lee, Cindy
Augustson, Bradley
Daly, James
INTERNAL MEDICINE JOURNAL, 2018, 48 (02) : 210 - 220
[24] Anti-CD38 Nanoantibody (JK36) Allows Detection of Minimal Residual Disease in Multiple Myeloma Patients Treated with Daratumumab
Souto, Elizabeth Xisto
Bento, Laiz Cameirao
Sousa, Flavia Arandas
Passaro, Marilia Sandoval
Vaz, Andressa Da Costa
Schimidell, Daniela
Bueno, Barbara Faziali
Myiamoto, Priscila Carmona
Nogueira, Bruna Garcia
Guerra, Joao Carlos
Villarinho, Andrea Rocco
Bacal, Nydia
BLOOD, 2023, 142
[25] DEVELOPMENT OF A MODEL OF RESISTANCE TO CYTOTOXICITY DEPENDENT COMPLEMENTS MEDIATED BY ANTI-CD38 MONOCLONAL ANTIBODIES IN MULTIPLE MYELOMA
Diaz-Tejedor, A.
Gonzalez-Mendez, L.
Algarin, E. M.
Martin-Sanchez, M.
San-Segundo, L.
Mogollon, P.
Hernandez-Garcia, S.
Benayas, B.
Garayoa, M.
Ocio, E. M.
Paino, T.
HAEMATOLOGICA, 2018, 103 : 85 - 85
[26] Anti-CD38 VHH antibody JK36 reliably detects CD38 in daratumumab treated multiple myeloma patients with high relevance for MRD diagnostics
Ecker, V
Mueller, M. L.
Haferlach, C.
Haferlach, T.
Kern, W.
ONCOLOGY RESEARCH AND TREATMENT, 2023, 46 : 232 - 233
[27] Mechanisms of resistance to daratumumab in patients with multiple myeloma
Iversen, Katrine Fladeland
BASIC & CLINICAL PHARMACOLOGY & TOXICOLOGY, 2024, 135 (04) : 401 - 408
[28] CLINICAL CHARACTERISTICS AND EVOLUTION OF PATIENTS WITH MULTIPLE MYELOMA RESISTANT TO ANTI-CD38 TREATMENT
Herreros Irene, Zamanillo
Paula Rosalia, De la Puerta
Manso Rodrigo, Gil
Garcia Rodrigo, Iniguez
Santaella Maria, Poza
Guerrero Elena, Vera
Soto Marta, Hidalgo
Maria de las Nieves, Lopez Munoz
Gil Rafael, Colmenares
Alos Daniel, Gil
Fernandez Rafael, Alonso
Teresa, Cedena Romero
Robles Maria, Calbacho
Diaz Rosa, Ayala
Joaquin, Martinez-Lopez
HAEMATOLOGICA, 2021, 106 (10) : 143 - 144
[29] ENGINEERED ANTI-CD38 MONOCLONAL-ANTIBODIES FOR IMMUNOTHERAPY OF MULTIPLE-MYELOMA
ELLIS, JH
BARBER, KA
TUTT, A
HALE, C
LEWIS, AP
GLENNIE, MJ
STEVENSON, GT
CROWE, JS
JOURNAL OF IMMUNOLOGY, 1995, 155 (02): : 925 - 937
[30] Anti-CD38 Pretargeted Radioimmunotherapy Eradicates Multiple Myeloma Xenografts In a Murine Model
Green, Damian J.
Jones, Jon C.
Hylarides, Mark D.
Hamlin, Donald K.
Wilbur, D. Scott
Lin, Yukang
Kenoyer, Aimee L.
Frayo, Shani L.
Bensinger, William I.
Gopal, Ajay K.
Orozco, Johnnie J.
Gooley, Theodore A.
Wood, Brent L.
Pagel, John M.
Press, Oliver W.
BLOOD, 2013, 122 (21)

← 1 2 3 4 5 →